Philips acquires U.S. AI firm SpectraWAVE to expand heart disease treatment technology

Philips has acquired U.S.-based company SpectraWAVE, which uses artificial intelligence (AI) to map and assess blood vessels, a move the Dutch healthcare technology firm says will enhance treatment for patients with coronary heart disease, including heart attacks.

SpectraWAVE, founded in 2017 and based in Bedford, Massachusetts, employs more than seventy people.

The financial terms of the acquisition have not been disclosed. Philips said the purchase will allow SpectraWAVE’s technology to be deployed on a larger scale.

Philips already has a broad portfolio of image-guided therapy solutions. Its Azurion platform, launched in 2017, integrates these tools and is used annually in the treatment of more than 7.6 million patients across more than 80 countries.

The company stated that combining SpectraWAVE’s AI-driven vascular mapping with its existing systems will strengthen its capabilities in diagnosing and treating coronary artery disease, the most common form of heart disease.